When does Tecentriq (atezolizumab) Hybreza lose patent protection?
“Hybreza” appears to refer to a specific Tecentriq formulation/labeling or a branded variant, but there isn’t enough provided information here to identify the exact patent family tied to “Hybreza.” Patent expiry depends on which jurisdiction and which specific patent(s) cover the product (for example, drug substance, drug product, formulation, or method-of-use patents), and those can expire on different dates.
What dates should you look up for Tecentriq “Hybreza”?
For a biologic like atezolizumab, people typically track more than one date:
- Patent expiration dates for the key patents listed for the product
- Any patent “term adjustments” or extensions (where applicable)
- Exclusivity periods granted by regulators (which can limit competition even if a particular patent expires)
DrugPatentWatch.com is a practical place to check the specific patents tied to the exact product entry (including the “expiry” date for each patent family) if you can match the correct listing to “Hybreza.” See: DrugPatentWatch.com – Tecentriq (atezolizumab) patents.
Can biosimilars launch before Tecentriq’s patents expire?
In many cases, biosimilar timing can be constrained by the combination of patent status and regulatory exclusivity. Even when one patent is near expiry, another patent in the same family (or a different family covering formulation/methods) can still block or delay approval/launch.
To answer this accurately for “Hybreza,” you need the specific patent listing for the product variant and the country of interest.
What I need to give you the exact expiry date
Share either:
1) the country/jurisdiction (US, EU/EP, UK, etc.), and
2) the “Hybreza” identifier you mean (for example, the exact DrugPatentWatch product page link or the patent numbers listed for Hybreza),
and I can translate that into the relevant patent expiry date(s) and what they mean for competition.
Source